Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study.
Albert Prats-UribeAnthony G SenaLana Yin Hui LaiWaheed-Ul-Rahman AhmedHeba AlghoulOsaid AlserThamir M AlshammariCarlos AreiaWilliam CarterPaula CasajustDalia DawoudAsieh GolozarJitendra JonnagaddalaParas P MehtaMengchun GongDaniel R MoralesFredrik NybergJose D PosadaMartina RecaldeElena RoelKarishma ShahNigam H ShahLisa M SchillingVignesh SubbianDavid VizcayaLin ZhangYing ZhangHong ZhuLi LiuJaehyeong ChoKristine E LynchMichael E MathenySeng Chan YouPeter R RijnbeekGeorge HripcsakJennifer Ce LaneEdward BurnChristian ReichMarc A SuchardTalita Duarte-SallesKristin KostkaPatrick B RyanDaniel Prieto-AlhambraPublished in: BMJ (Clinical research ed.) (2021)
Multiple drugs were used in the first few months of the covid-19 pandemic, with substantial geographical and temporal variation. Hydroxychloroquine, azithromycin, lopinavir-ritonavir, and umifenovir (in China only) were the most prescribed repurposed drugs. Antithrombotics, antibiotics, H2 receptor antagonists, and corticosteroids were often used as adjunctive treatments. Research is needed on the comparative risk and benefit of these treatments in the management of covid-19.